Home Health Care Stock on the Move: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Stock on the Move: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)


Intraday Info: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) locked on 15/12/2016 at $12.50. It has average volume $6.68 million whilst it total volume $3.48M. The company has EPS -0.18 and according to analysts next quarter EPS and next year estimate EPS will -0.18 and -0.46 respectively. Profit Margin of ARIA -17.00% and it total income 31.60 million.

Ownership Summary: Ariad Pharmaceuticals Inc has total institutional ownership 86.28% while its total outstanding shares 194 millions that’s value of holdings $2,099 million.

Active Positions: In the latest year, ARIA 111 holders have raised its positions while it contains total 54,346,863 shares. And the strength of reduced positions holders and held positions holders are 92 and 31 respectively.

New and Sold Out Positions: In ARIA force of new positions holders 49 and it has total shares 28,639,044. And force of sold out positions holders 29 and it has 7,914,798 shares.

Comparison with Other Company: The Market Value of ARIA is $2M below from Seattle Genetics, Inc. market value which is $8M. Current Last Sale of ARIA is $12.5 below from SGEN current last sale which is $63.73.

Ariad Pharmaceuticals, Inc. declared medical facts on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in ALK-high quality (ALK+) non-small mobile lung most cancers (NSCLC) patients who had practiced disease development on crizotinib therapy. As of may 31, 2016, the facts display that of sufferers on the 180-mg routine with a mean follow-up of eleven months, fifty five percentage accomplished confirmed goal response as assessed by the investigator. on this arm, the median development-free survival (PFS) changed into 15.6 months on this post-crizotinib putting, by way of both investigator and impartial evaluation committee (IRC) evaluation. further To, on this arm, sixty seven percent of patients with measurable mind metastases carried out a showed intracranial objective response, and intracranial PFS become 18.4 months amongst patients with any mind metastases at baseline. these facts could be provided recently at the international association for the take a look at of Lung cancer (IASLC) seventeenth world conference on Lung cancer (WCLC) being held in Vienna.